アクシアルディストニアとアセタゾラミド反応性無呼吸症候群

Gwen Zeigler¹, Miriam Quinlan¹, Panayiotis N Varelas¹

¹Department of Neurology, Albany Medical Center, 43 New Scotland Ave. MC-70, Albany, NY 12208, USA.

Clinical neurology and neurosurgery

|August 22, 2025

まとめ

このケーススタディは,ディストニックなと中央低気圧を伴う抗IgLON5疾患を強調しています. アセタゾラミドは希少な自己免疫神経疾患の新発見である低呼吸症を効果的に治療しました.

科学分野:

神経科学
免疫学
睡眠医学

背景:

抗免疫グロブリンIgLON5 (IgLON5) 疾患は珍しい自己免疫疾患である.
運動障害や睡眠障害を含む神経学的症状のスペクトルによって特徴付けられます.

研究の目的:

主要な軸性ディストニアと中央性低気圧による抗IgLON5疾患を報告する.
この状態における中央低気圧管理におけるアセタゾラミドの新規かつ効果的な使用について説明する.

主な方法:

67歳の男性の臨床症例です
診断には脳MRIと脳脊髄液 (CSF) のIgLON5抗体の分析が含まれていた.
治療には免疫療法 (IVIg,プラズマ交換,リトキシマブ) とアセタゾラミドが含まれていた.

主要な成果:

患者さんは子宮頸部と上半身のダストニックな,幻覚,手震えを呈した.
CSFはIgLON5抗体の存在を確認した.
免疫療法では症状がわずかに改善されたが,アセタゾラミドは中央低気圧の悪化を効果的に緩和した.
アクシアル・ディストニア,特にアンテロコリスは重要な特徴でした.

結論:

アクシアル・ディストニアは,抗IgLON5疾患の顕著な症状である可能性があります.
アセタゾラミドは,抗IgLON5疾患における中央低呼吸症候群の潜在的な治療法であり,この症状における最初の報告された使用である.

キーワード:

アセタゾラミドアンチイグロン5 アプネアディストニア呼吸不全

さらに関連する動画

06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

1.0K

10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.5K

関連する概念動画

01:20

Myasthenia Gravis: Overview and Treatment

1.9K

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

1.9K

01:24

Parkinson's Disease: Treatment

377

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

377

01:20

Antiepileptic Drugs: Potassium Channel Activators

274

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

274

01:15

Myasthenia Gravis: Diagnostic Tests

1.3K

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

1.3K

01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

754

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

754

01:14

Antiepileptic Drugs: Glutamate Antagonists

512

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

512

関連する実験動画